Aerie Pharmaceuticals Elects Murray Goldberg to the Company’s Board of Directors

  Aerie Pharmaceuticals Elects Murray Goldberg to the Company’s Board of
  Directors

Business Wire

BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. -- August 19, 2013

Aerie Pharmaceuticals, Inc. announced today that Murray Goldberg has been
elected to the Company’s Board of Directors, effective August 19, 2013. Mr.
Goldberg has had a successful career in corporate finance and banking, and he
has served as Chief Financial Officer of Regeneron Pharmaceuticals, Inc. since
1995. With the election of Mr. Goldberg to Aerie’s Board, the Company’s
directors now number eight.

“Murray Goldberg brings diverse financial experience and invaluable expertise
having played a critical role in growing a leading life sciences firm with a
major ophthalmology product on the market,” stated Vicente Anido, Jr., Ph.D.,
Chief Executive Officer and Chairman of Aerie Pharmaceuticals. “We are pleased
to welcome Murray to the Aerie Board and look forward to his contributions to
our continuing progress.”

As Chief Financial Officer at Regeneron, Mr. Goldberg is responsible for
managing all facets of the company’s financial activities and has contributed
to the strategic success of the company and generation of significant
shareholder value. During his tenure, Regeneron advanced from being an
early-stage public company to a commercial organization with three products on
the market, including EYLEA® (aflibercept) Injection, an innovative therapy
for patients with neovascular (wet) age-related macular degeneration (AMD).
Prior to joining Regeneron, Mr. Goldberg was Vice President, Finance,
Treasurer, Chief Financial Officer and a Director of the private biotechnology
company PharmaGenics, Inc. Previously, Mr. Goldberg was Managing Director,
Structured Finance Group at the Chase Manhattan Bank, N.A., and prior to this,
he served in various managerial positions in finance and corporate development
at American Cyanamid Company. Mr. Goldberg received his M.B.A. degree from the
University of Chicago, his M.Sc. degree in Economics from the London School of
Economics, and his B.E. degree in Industrial Engineering from New York
University.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals is a privately held pharmaceutical company in late Phase
2 dedicated to the discovery and development of novel small-molecule
treatments for glaucoma. Aerie’s internal research and development engine has
generated an innovative glaucoma pipeline of proprietary product candidates,
which are well tolerated, high efficacy, once-daily eye drop therapies that
include the first new mechanisms of action for glaucoma treatment in nearly 20
years.

The Company’s lead product candidate, AR-13324, is the first of a new dual
action drug class that reduces the eye’s fluid inflow while also increasing
fluid outflow through the trabecular meshwork, which is the eye’s main fluid
drain, all in a highly effective single drop per day. Aerie’s PG324 fixed
combination of AR-13324 with latanoprost is a first-in-class glaucoma therapy
to lower intraocular pressure by reducing fluid inflow while also opening both
of the eye’s fluid drains. This product candidate offers the convenience of
two drugs in one eye drop.

Aerie is located in Bedminster, New Jersey and Research Triangle Park, North
Carolina. Further information on the Company is available at
www.aeriepharma.com.

Contact:

Aerie Pharmaceuticals
Richard Rubino, (908) 470-4320
rrubino@aeriepharma.com
or
Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals
Justin Jackson, (212) 213-0006
jjackson@burnsmc.com